Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
Precigen, Inc., a Virginia corporation, filed this Current Report on Form 8-K on May 13, 2026. The filing serves to announce the company's financial results for the quarter ended March 31, 2026. The company's common stock trades on the Nasdaq Global Select Market under the symbol PGEN.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
No specific material changes versus the prior comparable period are described in the provided text. The filing indicates that results for the quarter ended March 31, 2026, are reported in the attached exhibit.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It explicitly states that the information in the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 13, 2026) for actual revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter performance trends in the attached press release.
- Confirm the company's liquidity position and cash runway as detailed in the full financial report.
- Check for any updated clinical trial milestones or regulatory developments mentioned in the press release.